Srinivas Sadu

We remain confident in sustaining this momentum, supported by a pipeline of complex product launches and the continued ramp-up of CDMO partnerships.

Cenexi is now EBITDA positive, operationally stable and poised for growth.

The forecasting or the guidance we give is excluding GLP-1. Anything which happens on GLP-1 will run upside.

India pharma is moving from being the pharmacy of the world to becoming a global innovation hub.

We have signed up with several, Semaglutide, the generics also.

Our strategy is focused on four key aspects: growth, capability, efficiency, and ROC. All aligned towards building Gland Pharma into a high-end, innovation-driven CDMO and specialty injectables company.

We are estimating the EBITDA ramp-up happening in Q3 and then Q4 also. Q2 would be a little lower because of the one-month summer shutdown.

We are looking at mid-teens as a growth for the coming year.

We expect to recover these volumes in the coming quarters and remain optimistic about the overall trajectory of our business.

The initial financial benefits we'll get from the first quarter of next year, and then, depending on the timing of the products and the development, then it will pick up.

We have already signed a few GLP-1 contracts on the CDMO side.

We are in discussions with a leading biologics company for a potential strategic collaboration. This collaboration could involve large-scale contract manufacturing of our four biosimilars with a possible in-licensing opportunity for Gland Pharma in specific markets of interest.